Targeted radiation for a few prostate cancer metastases
Treatments studied
Part of Cancer clinical trials.
This trial looks at whether a precise form of radiation (stereotactic body radiotherapy) can control a small number of prostate cancer spots seen on a special scan (PSMA PET/CT). It may help by treating limited metastases while avoiding unnecessary treatment elsewhere.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed prostate cancer diagnosed by biopsy (pathology-confirmed).
- Your health and daily functioning are good (ECOG 0–1).
- Your scan shows 1–3 metastases limited to bones or lymph nodes, not more than that.
- You have hormone-sensitive prostate cancer (not castration-resistant).
- You have not had prostate cancer treatments that affect PSA in the last 6 months, unless started very close to enrollment due to the limited metastases.
- You can be treated with the planned radiation safely, and you have no prior radiation or surgery that would interfere with the radiation plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two newer treatments—targeted radiation (SABR) or a special radioactive drug (Lu-177 PSMA-617)—added to standard hormone therapy for men with prostate cancer that has spread. The goal is to see if these additional treatments help control the cancer better.
This Phase 3 trial tests whether treating only a small number of prostate cancer metastases can help people with “oligorecurrent” (limited repeat) prostate cancer. It may reduce cancer activity while avoiding broader whole-body treatment for some patients.
This trial tests whether adding a PSMA-targeted radioactive medicine (Lu-PSMA) to focused stereotactic radiation to a few prostate cancer spots works better than radiation alone. It may help people with limited, asymptomatic spread of prostate cancer by improving cancer control while carefully monitoring side effects.
This trial uses a special PET/MR scan to help doctors aim stereotactic radiation more precisely for certain higher-risk or unfavorable intermediate prostate cancers. It studies whether this targeted approach can safely treat the prostate (and specific areas needing extra treatment) without spreading to the body.
This trial studies the use of radiation to the prostate and to all visible spots where cancer has spread, in men who have up to 10 small areas of spread when first diagnosed. The goal is to see if this approach can help control the cancer.
This trial uses a special PET scan (POSLUMA) before and after radiation to see if it helps treat prostate cancer that has spread to a few spots outside the pelvis. It's for men whose cancer still responds to hormone therapy and who have not had widespread spread.
Hear when a new Radiation Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.